Side-by-side · Research reference
BronchogenvsChonluten
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED16/35 cited
BAnimal-MechanisticHUMAN-REVIEWED8/38 cited
Bronchogen
Tetrapeptide Bioregulator · Khavinson-School
Research models: tissue culture / parenteral
Chonluten
Khavinson Bioregulator · Bronchial Mucosa
Oral · Sublingual · Per Protocol
01Mechanism of Action
Parameter
Bronchogen
Chonluten
Primary target
Bronchial epithelial cellsKuzubova 2015
Bronchial epithelial cells and respiratory mucosa tissue complexes
Pathway
Tissue-specific bioregulation → epithelial cell differentiation → ciliated cell restoration
Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populationsAvolio 2022
Downstream effect
Reversal of goblet cell hyperplasia, squamous metaplasia elimination, restoration of ciliated epithelium, normalized secretory IgA and surfactant protein B productionKuzubova 2015Titova 2017
Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cellsAvolio 2022
Feedback intact?
—
—
Origin
Synthetic tetrapeptide (Ala-Glu-Asp-Leu) from Khavinson bioregulator framework
Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology
Antibody development
—
—
02Dosage Protocols
Parameter
Bronchogen
Chonluten
Effective concentration (culture)
0.05 ng/mLZakutskiĭ 2006
Demonstrated in organotypic tissue culture of bronchial explants.
—
Treatment duration (animal)
1 month (30 days)Kuzubova 2015Titova 2017
Course duration in rat COPD models.
—
Evidence basis
Animal models (rat) / organotypic cultureTitova 2017Kuzubova 2015Zakutskiĭ 2006
No human clinical trials reported in available literature.
In vitro mechanistic
Tissue specificity
Selective for bronchopulmonary tissue
Part of Khavinson organ-specific bioregulator series.
—
Typical protocol dose
—
10–20 mg / day
Russian bioregulator tradition dosing; not standardized in Western literature.
Frequency
—
Once or twice daily
Route
—
Oral (capsule) or sublingual
Sublingual claimed for enhanced bioavailability; not validated.
Duration
—
10–30 days per cycle
Traditional Khavinson protocol; cyclic administration common.
Clinical validation
—
None (PubMed indexed)
04Side Effects & Safety
Parameter
Bronchogen
Chonluten
Animal safety profile
No adverse effects reported in published rat studies
Limited safety data; only animal models available.
—
Human data
Absent — no clinical trials in humans reported
—
Long-term effects
Unknown — maximum study duration 30 days in animals
—
Documented adverse events
—
No published safety data in PubMed-indexed literature
Theoretical risks
—
Peptide hypersensitivity, GI intolerance (uncharacterized)
Drug interactions
—
Unknown — no pharmacokinetic studies available
Pregnancy / lactation
—
No data — avoid
Absolute Contraindications
Bronchogen
—Chonluten
- ·Known hypersensitivity to peptide components
Relative Contraindications
Bronchogen
—Chonluten
- ·Pregnancy and lactation (insufficient data)
- ·Active malignancy (theoretical bioregulator concern)
05Administration Protocol
Parameter
Bronchogen
Chonluten
1. Research context only
Bronchogen has been studied exclusively in animal models and organotypic tissue culture. No approved formulation or human administration protocol exists.
Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.
2. Animal model protocol
In rat COPD models, tetrapeptide administered for 30-day course following 60-day NO₂ exposure. Route and exact dosing not specified in abstracts.Titova 2017Kuzubova 2015
Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.
3. Organotypic culture
Bronchial tissue explants from young (3-week) and aged (18-month) rats cultured in medium containing 0.05 ng/mL bronchogen, demonstrating tissue-specific stimulation.Zakutskiĭ 2006
Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.
4. Khavinson bioregulator tradition
Part of Russian peptide bioregulator framework emphasizing tissue-specific low-dose effects. Typically administered parenterally in related peptides from this series.
Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.
5. Cycle protocol
—
10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.